English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Pharma & Biotech Clinical Trials
Avance Clinical在2022年生物技术展上宣布为美国扩张进行重大私募股权投资
Jan 19, 2022 07:00 HKT
Avance Clinical在2022年生物技術展上宣佈為美國擴張進行重大私募股權投資
Jan 19, 2022 07:00 HKT
아방스 클리니컬 바이오테크 쇼케이스 2022에서 미국에서의 확장을 위한 대규모적인 PE 투자를 발표
Jan 19, 2022 07:00 HKT
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022
Jan 18, 2022 13:00 HKT
冠科美博 (Apollomics Inc.) 将于 2022 年 1 月 26-27 日(周三、周四)举办线上投资者活动
Jan 12, 2022 09:27 HKT
冠科美博 (Apollomics Inc.) 將於 2022 年 1 月 26-27 日(週三、週四)舉辦線上投資者活動
Jan 12, 2022 09:26 HKT
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Jan 12, 2022 09:25 HKT
B-cell lymphoma clinical trials now open on the TrialWire Platform
Jan 05, 2022 17:10 HKT
Autism clinical trials now open on the TrialWire Platform
Jan 05, 2022 17:00 HKT
冠科美博(Apollomics)首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席
Jan 04, 2022 10:12 HKT
冠科美博(Apollomics)首席執行官余國良博士當選為百華協會 (BayHelix Group) 董事會主席
Jan 04, 2022 10:11 HKT
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Jan 04, 2022 10:10 HKT
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
Nov 22, 2021 10:42 HKT
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組
Nov 22, 2021 10:41 HKT
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Nov 22, 2021 10:40 HKT
Olympus Launches Venture Capital Fund to Strengthen Medtech Leadership
Nov 12, 2021 07:30 HKT
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
Oct 19, 2021 15:00 HKT
Avance Clinical Client News: XWPharma Initiates First-in-Human Studies of XW10508, in Development for Fast-acting Relief of Treatment-Resistant Depression and Chronic Pain
Oct 19, 2021 15:00 HKT
Avance Clinical临床试验合作申办方XWPharma正式开启其XW10508首次人类临床试验,研究快速缓解难治性抑郁症以及慢性疼痛疗法
Oct 19, 2021 15:00 HKT
Avance Clinical臨床試驗合作申辦方XWPharma正式開啟其XW10508首次人類臨床試驗,研究快速緩解難治性抑鬱症以及慢性疼痛療法
Oct 19, 2021 15:00 HKT
Next >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: